OGC
ARCT icon

One68 Global Capital’s Arcturus Therapeutics ARCT Stock Holding History

One68 Global Capital’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-19,861
Closed -$216K – 15
2019
Q4 		$216K Buy
+19,861
New +$208K 0.47% 35

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
DI
DFPG Investments Sandy, Utah $1.28B AUM 27.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

One68 Global Capital's ARCT Position: Q1 2020 in Review

One68 Global Capital sold out of Arcturus Therapeutics (ARCT) in Q1 2020, closing a stake of 19,861 shares — an estimated $216K sold.

One68 Global Capital first reported a position in ARCT in Q4 2019 and held it in 1 quarter. The position peaked at $216K in Q4 2019. 53 funds tracked by Wall St. Rank hold ARCT as of Q1 2020.

  • One68 Global Capital reported no remaining Arcturus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • One68 Global Capital sold 19,861 Arcturus Therapeutics shares in Q1 2020, an estimated $216K.
  • One68 Global Capital first reported a position in Arcturus Therapeutics in Q4 2019 and held it in 1 quarter.
  • One68 Global Capital's Arcturus Therapeutics position peaked at $216K in Q4 2019.
  • 53 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2020.

Based on One68 Global Capital's 13F filing for Q1 2020, filed 15 May 2020.